07.14.26 -- Mapping Early-Phase Supply Chain Bottlenecks That Doom Pipelines

Delve into why investing in a comprehensive feasibility program for GOI testing is not just beneficial, but absolutely essential for cell and gene therapy companies.

Accelerate genomic medicine by comparing five editing modalities, engineering new enzymes, and rapidly pinpointing optimal strategies that boost feasibility, cut risk, and speed clinical progress.

Strategic tech transfer and scalable manufacturing enabled rapid NDA approval, delivering registration batches and accelerating commercialization of a novel therapy for drug-resistant infections.

Development partnerships start with early alignment, transparency, and shared accountability, reducing risk, improving scalability, and supporting success as programs advance.

Dive into the scope of <382> for pharmaceutical closures and the regulatory landscape, which includes new required tests, instrumentation for compliance, and recommendations on implementation.

Reliable temperature‑controlled storage, monitoring, and safeguards keep sensitive materials stable from fill to patient, protecting quality, preventing degradation, and ensuring safety throughout the cold chain.

Biologics development leaders discuss industry challenges, including innovation pressures, operational complexity, leadership decisions, and maintaining quality and resilience in an evolving landscape.

View antibody-oligonucleotide conjugate design, highlighting antibody formats, linker strategies, and screening methods to optimize delivery, stability, and gene-targeting therapeutic performance.

High particle counts don’t always mean high risk. Identifying particle type and origin—not just quantity—avoids false alarms, protects timelines, and turns data into action.

An on‑demand session showing how integrated governance and real‑time data boost visibility, collaboration, and control in outsourced gene therapy development.

A novel valve provides dual‑chamber functionality within standard syringes, keeping two liquid drugs separated until injection while reducing development risk through advanced modeling.